A 58-Year-Old Man With Moderate Steroid-Refractory Chronic Graft-Versus-Host Disease

Pashna Munshi, MD, discusses the treatment of a 58-year-old man who developed moderate steroid-refractory chronic graft-versus-host disease (cGVHD) after a stem cell transplant, and briefly reviews risk factors for developing cGVHD.

An overview of common symptoms, diagnostic challenges, and tools for severity assessment of chronic graft-versus-host disease.

Pashna Munshi, MD reviews risk factors for steroid-refractory cGVHD and the clinical challenges of identification, treatment, and management of the disease.

A focused discussion on available treatment options for patients with steroid-refractory cGVHD.

Pashna Munshi, MD, expands upon ruxolitinib’s mechanism of action in steroid-refractory cGVHD and discusses REACH3 efficacy data.

A comprehensive review of recent real-world ruxolitinib efficacy data and the use of emerging prognostic markers to risk-stratify patients with cGVHD.

Pashna Munshi, MD, provides an overview of adverse event data from the REACH3 trial of ruxolitinib in patients with steroid-refractory cGVHD and discusses management of patients’ side effects in clinical practice.

A commentary on the patient’s case and strategies for treatment selection and management for those with steroid-refractory disease.

Pashna Munshi, MD, wraps up by talking about future directions and emerging treatment regimens in the field of GVHD.